polyneuropathy

(redirected from Familial amyloid polyneuropathy)
Also found in: Medical, Wikipedia.
Related to Familial amyloid polyneuropathy: Amyloid angiopathy
Translations

pol·y·neu·rop·a·thy

n. polineuropatía, enfermedad que afecta varios nervios a la vez.

polyneuropathy

n polineuropatía
References in periodicals archive ?
Treatment with this therapy delays neurologic progression in transthyretin familial amyloid polyneuropathy, a similar condition in which amyloid is deposited in the nerves after transthyretin misfolding.
Depending on the type of mutation, manifestations can range from cardiac involvement (familial cardiac amyloidosis), peripheral nerve damage (familial amyloid polyneuropathy), and overlapping phenotypes [4].
Andreani et al., "Operative risks of domino liver transplantation for the familial amyloid polyneuropathy liver donor and recipient: A double analysis," American Journal of Transplantation, vol.
Adams et al., "Ocular involvement in familial amyloid polyneuropathy," Journal Francais d'Ophtalmologie, vol.
Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial.
The most common forms of amyloidosis include systemic AL amyloidosis (formerly primary amyloidosis), systemic AA amyloidosis (formerly secondary amyloidosis), systemic wild-type ATTR amyloidosis (formerly age-related or senile systemic amyloidosis), systemic hereditary ATTR amyloidosis (formerly familial amyloid polyneuropathy), and localized AL amyloidosis (Table 1).
Clinical variability in type I familial amyloid polyneuropathy (Val30Met): Comparison between lateand early-onset cases in Portugal.
Familial amyloid polyneuropathy (FAP) type IV (FINNISH) is a very rare life-threatening disorder and reported only in a few countries.
Global Markets Direct's, 'Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease) - Pipeline Review, H2 2015', provides an overview of the Familial Amyloid Polyneuropathy (Transthyretin Amyloidosis, Corino de Andrade's Disease)'s therapeutic pipeline.
Familial amyloid polyneuropathy. Lancet Neurol 2011;10:1086-97.
has earned a $15 million milestone payment from GSK related to advancing the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).
Da Silva et al., "Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial," Neurology, vol.
Full browser ?